Eli Lilly and Company (LLY)vsWeave Communications Inc (WEAV)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
WEAV
Weave Communications Inc
$4.93
+1.76%
HEALTHCARE · Cap: $391.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 27169% more annual revenue ($65.18B vs $239.02M). LLY leads profitability with a 31.7% profit margin vs -11.7%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
WEAV
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+54.0%
Fair Value
$13.04
Current Price
$4.92
$8.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
17.0% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -37.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : WEAV
The strongest argument for WEAV centers on Revenue Growth. Revenue growth of 17.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : WEAV
The primary concerns for WEAV are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
WEAV carries more volatility with a beta of 1.71 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 31.7% margins and 42.6% revenue growth. WEAV offers better value entry with a 54.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Weave Communications Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Weave Communications, Inc. provides a customer communication and interaction software platform in the United States and Canada. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?